WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise

• The company expects to file applications to begin human testing for several of the new programs within the next 12 to 24 months.
• Earlier this month, the company announced an $87.5 million private placement equity financing.
• According to data from Koyfin, three of the six analysts covering WHWK rate it 'Buy' or higher, while the other three rate it ‘Hold.’

Shares of Whitehawk Therapeutics Inc. (WHWK) edged 2% higher in after-hours trading on Thursday after the clinical-stage oncology company announced a new option agreement that expands its pipeline of next-generation cancer treatments.

Whitehawk said it has secured rights from the firm Hangzhou DAC to use the CPT113 linker-payload technology in up to five additional internally developed programs. Antibody-drug conjugates, or ADCs, are precision therapies that combine an antibody — which homes in on cancer cells — with a potent toxin to attack tumors while minimizing damage to healthy tissue.

Under the deal, Whitehawk will pick its own targets, supply the antibodies, and retain full global rights and control over the new programs. The company expects to file applications to begin human testing for several of them within the next 12 to 24 months.

Whitehawk currently has two candidates — HWK-007 and HWK-016 — enrolling patients in early-stage clinical trials for certain lung, ovarian, and endometrial cancers. A third program, HWK-206, is on track for regulatory clearance to start testing around mid-year.

Whitehawk’s pipeline expansion is backed by fresh capital. Earlier this month, the company announced an $87.5 million private placement equity financing. Proceeds, together with existing cash, are expected to extend Whitehawk’s runway into the second half of 2028 and will be used to advance its ADC pipeline, the company then said.

WHWK’s Retail Sentiment

On Stocktwits, retail sentiment around WHWK stock fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours, while message volume improved from extremely high to low levels.

According to data from Koyfin, three of the six analysts covering WHWK rate it Buy or higher, while the other three rate it ‘Hold.’ The 12-month average price target on the stock is $6.5, representing a potential upside of over 51%.

WHWK stock has gained 123% over the past 12 months. 

Read More: AKTX Stock Goes Parabolic After Hours On $5.5M Capital Raise, Cancer Data Win: Wall Street Sees 400% Upside

For updates and corrections, email newsroom[at]stocktwits[dot]com.